CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...